Drug Importation: Biden Response To PhRMA Suit Highlights Infeasibility Of Trump-Era Rule
Executive Summary
Biden administration asks court to dismiss PhRMA’s lawsuit against Trump-era pathway for drug importation from Canada because FDA has not yet cleared any Section 804 Importation Programs (SIPs). The brief outlines the high hurdles to getting a SIP approved and Canada’s opposition to the programs. It's not clear if the Biden team plans another more feasible route to drug importation.
You may also be interested in...
Canada Counters Drug Shortages With Export Bans
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
PhRMA Sues To Block HHS Drug Importation Rule Citing Security, Safety, First Amendment Concerns
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.
COVID-Era Trial Flexibilities, Equity Focus, Could Be Used To Reshape Cancer Study Enrollment
US FDA is open to keeping COVID-necessitated trial changes that may have had unexpected benefits. The agency is also looking at building on pandemic’s focus on health disparities and inequities to push for more generalizable and inclusive clinical trial designs.